NASDAQ:TVTX Travere Therapeutics (TVTX) Stock Price, News & Analysis $10.98 +1.05 (+10.57%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$10.64▼$11.9150-Day Range$7.89▼$10.9852-Week Range$5.12▼$14.82Volume7.89 million shsAverage Volume1.23 million shsMarket Capitalization$835.90 millionP/E RatioN/ADividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Travere Therapeutics alerts: Email Address Travere Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.62 Rating ScoreUpside/Downside48.8% Upside$16.33 Price TargetShort InterestHealthy12.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 19 Articles This WeekInsider TradingSelling Shares$4,888 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.98) to ($1.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.85 out of 5 starsMedical Sector365th out of 910 stocksPharmaceutical Preparations Industry160th out of 426 stocks 4.3 Analyst's Opinion Consensus RatingTravere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.62, and is based on 8 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageTravere Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Travere Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.22% of the outstanding shares of Travere Therapeutics have been sold short.Short Interest Ratio / Days to CoverTravere Therapeutics has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Travere Therapeutics has recently decreased by 7.83%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTravere Therapeutics does not currently pay a dividend.Dividend GrowthTravere Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TVTX. Previous Next 2.5 News and Social Media Coverage News SentimentTravere Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Travere Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,888.00 in company stock.Percentage Held by InsidersOnly 3.75% of the stock of Travere Therapeutics is held by insiders.Read more about Travere Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Travere Therapeutics are expected to grow in the coming year, from ($3.98) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Travere Therapeutics is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Travere Therapeutics is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTravere Therapeutics has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Travere Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Travere Therapeutics Stock (NASDAQ:TVTX)Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More TVTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TVTX Stock News HeadlinesSeptember 7 at 6:48 AM | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Price Target Raised to $19.00 at Bank of AmericaSeptember 7 at 6:48 AM | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Price Target Increased to $23.00 by Analysts at CitigroupSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 7 at 1:39 AM | americanbankingnews.comTravere Therapeutics (NASDAQ:TVTX) Shares Gap Up Following Analyst UpgradeSeptember 6 at 7:53 PM | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Travere Therapeutics (TVTX)September 6 at 2:50 PM | marketwatch.comTravere Therapeutics Shares Rise on Full FDA Nod for Kidney DrugSeptember 6 at 2:50 PM | markets.businessinsider.comUpgraded Buy Rating and Target Price for Travere Therapeutics on Filspari’s Market Expansion and ApprovalSeptember 6 at 2:50 PM | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics as FDA Approval Expands FILSPARI’s Market ReachSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 6 at 9:57 AM | investors.comTravere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney DiseaseSeptember 5 at 5:34 PM | globenewswire.comTravere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA NephropathySeptember 3, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Buy from Evercore ISISeptember 2, 2024 | markets.businessinsider.comBiotech Stocks Facing FDA Decision In September 2024August 30, 2024 | markets.businessinsider.comPositive Outlook for Travere Therapeutics with Sparsentan’s Endorsement and Anticipated FDA ApprovalAugust 30, 2024 | seekingalpha.comTravere Therapeutics: Judgement Day Is Nigh For SparsentanAugust 30, 2024 | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Receives $15.67 Consensus Price Target from AnalystsAugust 23, 2024 | markets.businessinsider.comBuy Rating Affirmed: Travere Therapeutics’ Market Potential Bolstered by Regulatory Prospects and Sales PerformanceAugust 22, 2024 | morningstar.comTravere Therapeutics Inc Ordinary SharesSee More Headlines Receive TVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVTX CUSIPN/A CIK1438533 Webwww.retrophin.com Phone(888) 969-7879Fax302-645-1280Employees460Year FoundedN/APrice Target and Rating Average Stock Price Target$16.33 High Stock Price Target$23.00 Low Stock Price Target$9.00 Potential Upside/Downside+48.8%Consensus RatingModerate Buy Rating Score (0-4)2.62 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($2.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-111,400,000.00 Net Margins-82.14% Pretax Margin-215.65% Return on Equity-269.18% Return on Assets-54.08% Debt Debt-to-Equity Ratio24.96 Current Ratio3.04 Quick Ratio2.99 Sales & Book Value Annual Sales$177.64 million Price / Sales4.71 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book4.11Miscellaneous Outstanding Shares76,129,000Free Float73,274,000Market Cap$835.90 million OptionableOptionable Beta0.71 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Eric M. Dube Ph.D. (Age 50)President, CEO & Director Comp: $1.4MMr. Christopher Cline C.F.A. (Age 39)Chief Financial Officer Comp: $709.94kMs. Elizabeth E. Reed J.D. (Age 53)Senior VP, General Counsel & Corporate Secretary Comp: $713.63kDr. William E. Rote Ph.D. (Age 61)Senior VP and Head of Research & Development Comp: $748.02kMr. Peter Heerma (Age 52)Chief Commercial Officer Comp: $742.37kMs. Sandra Calvin (Age 58)SVP, Corporate Controller & Chief Accounting Officer Ms. Naomi EichenbaumVice President of Investor RelationsMs. Charlotte SmithSenior Vice President of Public AffairsMs. Angela GiannantonioSenior Vice President of Human ResourcesMr. Casey LoganChief Business OfficerMore ExecutivesKey CompetitorsHarrowNASDAQ:HROWEpizymeNASDAQ:EPZMRigel PharmaceuticalsNASDAQ:RIGLOmerosNASDAQ:OMERBiohavenNYSE:BHVNView All CompetitorsInsiders & InstitutionsChristopher R ClineSold 514 sharesTotal: $4,888.14 ($9.51/share)Forefront Analytics LLCBought 1,237 shares on 8/16/2024Ownership: 0.017%Millennium Management LLCBought 747,406 shares on 8/15/2024Ownership: 3.856%AQR Capital Management LLCBought 26,485 shares on 8/15/2024Ownership: 0.097%Point72 Asia Singapore Pte. Ltd.Bought 35,377 shares on 8/15/2024Ownership: 0.046%View All Insider TransactionsView All Institutional Transactions TVTX Stock Analysis - Frequently Asked Questions How have TVTX shares performed this year? Travere Therapeutics' stock was trading at $8.99 at the beginning of the year. Since then, TVTX stock has increased by 22.1% and is now trading at $10.98. View the best growth stocks for 2024 here. How were Travere Therapeutics' earnings last quarter? Travere Therapeutics, Inc. (NASDAQ:TVTX) issued its quarterly earnings results on Thursday, August, 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.03. The company earned $54.12 million during the quarter, compared to analysts' expectations of $49.50 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 269.18% and a negative net margin of 82.14%. Who are Travere Therapeutics' major shareholders? Travere Therapeutics' top institutional investors include Millennium Management LLC (3.86%), Assenagon Asset Management S.A. (2.91%), Renaissance Technologies LLC (2.89%) and Emerald Advisers LLC (2.15%). Insiders that own company stock include Eric M Dube, Steve Aselage, Peter Heerma, William E Rote, Christopher R Cline, Elizabeth E Reed, Sandra Calvin, Laura Clague and Jula Inrig. View institutional ownership trends. How do I buy shares of Travere Therapeutics? Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TVTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVTX Stock Alerts